Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

03 déc. 2024 04h00 HE | Source: Alveogene

AlveoGene’s Novel, Inhaled Gene Therapy AVG-002 Receives Orphan Drug Designation from FDA for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency

Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infants with few, if any, options for long-term survivalHighly encouraging preclinical data...
15 nov. 2024 04h00 HE | Source: Alveogene

AlveoGene Receives Rare Pediatric Disease Designation (RPDD) from FDA for AVG-002, its Novel, Inhaled Gene Therapy for Lethal Neonatal Surfactant Protein B (SP-B) Deficiency

Inherited SP-B deficiency is an ultra-rare monogenic cause of fatal respiratory distress syndrome in newborn infantsClinical estimates for SP-B deficiency have an incidence of 1 in 1 million live...
14 sept. 2023 03h00 HE | Source: Alveogene

AlveoGene Launches to Develop Unique Inhaled Gene Therapies for Rare Respiratory Disorders

New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the world-renowned UK...